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background:  Limited 5-year outcomes are available with second-generation drug eluting stents, including the Resolute zotarolimus-
eluting stent (R-ZES). Long-term data is particularly important in patients with diabetes mellitus (DM), who may have increased delayed or 
recurrent clinical events.
methods:  The RESOLUTE US (R-US) trial enrolled patients with de novo coronary lesions (lesion length ≤27 mm, vessel size >2.25 mm 
in one- or two-vessel treatment), with FDA-mandated annual clinical follow-up (FU), and CEC adjudication of all clinical events. Patients 
with DM were a pre-specified subset in the “main cohort” (2.5 to 3.5 mm diameter stents). 
results:  A total of 1402 patients (1,573 lesions), including 1112 patients (1221 lesions) in the main cohort were enrolled. 34% had DM, 
75% were treated for type B2/C lesions, and 10% received two-vessel treatment. At 4 years, the cumulative incidence of target lesion 
failure (TLF) was 10.1%; including clinically-driven target lesion revascularization (TLR) in 5.3%, target vessel myocardial infarction (TV-MI) 
in 2.6%, cardiac death in 2.9%, and ARC def/prob stent thrombosis (ST) in 0.4%. Between 1 and 4 years (late FU), TLF was 5.2%, TLR 
2.3%, TV-MI 1.2%, cardiac death 2.2%, and ARC def/prob ST 0.2%. Dual antiplatelet therapy was used in 93.8% and 51.4% of patients at 
1 and 4 years, respectively. There were no differences in any of the outcomes between patients with DM (N=374) vs. without DM (N=738) 
at any time point in the main cohort. Five-year results will be available at ACC 2015.
Conclusion:  R-ZES in the R-US trial was associated with (1) excellent clinical outcomes, including very low TLR and ST during late FU, 
and (2) similar outcomes in patients with DM vs. without DM. 
